Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Sep 24, 2024
The landscape of multiple myeloma therapies has been revolutionized by the introduction of cutting-edge monoclonal antibodies (mAbs) targeting CD38. Among the standout advancements are DARZALEX (daratumumab) and SARCLISA (isatuximab-irfc), which have emerged as game-changers in the treatment of multiple myeloma. Th...
Read More...
Jul 30, 2024
Multiple Myeloma, the second most common type of blood cancer after non-Hodgkin lymphoma, is characterized by the presence of malignant plasma cells in the bone marrow. The diagnosis involves identifying these highly abnormal and unstable cells, which proliferate aggressively and spread through the bloodstream and ...
Read More...
Jan 03, 2022
An antibody is a protein produced by the immune system in response to an infection in the body. Whereas, a monoclonal antibody is a molecule produced in a laboratory specifically designed to enhance the body’s natural immune system response against an invader, such as cancer or an infection. Monoclonal antibodies h...
Read More...
Jan 10, 2019
Apollomics raises USD 100 Million for funding of transpacific cancer R&D plan Apollomics has raised USD 100 million for funding an oncology clinical trial program. The series B round sets Apollomics to progress its c-Met inhibitor and pipeline of other clinical-phase assets. OrbiMed Asia-backed Apo...
Read More...
Aug 30, 2018
For all-in-one dialysis system, Outset Medical captures USD 132 Million to extend U.S. expansion Outset Medical bagged USD132 Million in series D capital. This ensued in encouraging the production capabilities and accelerating the commercial expansion for all-in-one dialysis system. The FDA cleared the Tablo Hemodia...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper